Predictive factors for the benefit of triple‐drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma-Reference-Cited by-同舟云学术

Predictive factors for the benefit of triple‐drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma

Published:2019-06-17 Issue:9 Volume:8 Page:4200-4213
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

He MinKe¹,Li Qing²,Shen JingXian³,Tan GuoSheng⁴,Li QiJiong¹,Lai JiaYing⁵,Wei Wei¹,Zhang YaoJun¹,Zou RuHai²,Chen MinShan¹,Guo RongPing¹,Shi Ming¹^ORCID

Affiliation:

1. Department of Hepatobiliary Oncology Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou China

2. Department of Ultrasonography Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou China

3. Department of Radiology Sun Yat‐sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Guangzhou China

4. Department of Interventional Radiology The First Affiliated Hospital of Sun Yat‐sen University Guangzhou China

5. HuiDong Senior Middle School Huidong China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2355

Reference41 articles.

1. Management of hepatocellular carcinoma: An update

2. EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

3. Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects

4. Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version

5. Korean Liver Cancer Study Group‐National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma;Korean Liver Cancer Study G, National Cancer Center K;Korean J Radiol,2014

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Lobaplatin-TACE in the Treatment of Primary Hepatocellular Carcinoma: A Retrospective Study;Anti-Cancer Agents in Medicinal Chemistry;2023-02

2. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib;Technology in Cancer Research & Treatment;2023-01

3. CFDP1 promotes hepatocellular carcinoma progression through activating NEDD4 / PTEN / PI3K / AKT signaling pathway;Cancer Medicine;2022-07-21

4. Analysis of complications after transcatheter arterial chemoembolization based on deep learning;The Journal of Supercomputing;2021-03-05

5. Transarterial chemoembolization as a palliative treatment for primary and secondary liver cancers: the 2013-2017 cohort of the Pilsen University Hospital;Onkologie;2021-01-08